OPKO Health, Inc. (NASDAQ:OPK) Shares Purchased by Comerica Bank

Comerica Bank grew its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK) by 18.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 106,369 shares of the biotechnology company’s stock after purchasing an additional 16,369 shares during the quarter. Comerica Bank’s holdings in OPKO Health were worth $156,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in OPK. Northern Trust Corp raised its position in shares of OPKO Health by 4.7% in the 4th quarter. Northern Trust Corp now owns 3,697,774 shares of the biotechnology company’s stock worth $5,436,000 after buying an additional 164,847 shares during the period. Altshuler Shaham Ltd acquired a new stake in shares of OPKO Health during the fourth quarter valued at about $2,082,000. Tejara Capital Ltd grew its stake in shares of OPKO Health by 11.3% during the fourth quarter. Tejara Capital Ltd now owns 1,225,650 shares of the biotechnology company’s stock valued at $1,802,000 after acquiring an additional 124,524 shares in the last quarter. PFG Investments LLC grew its stake in shares of OPKO Health by 9.4% during the fourth quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company’s stock valued at $1,707,000 after acquiring an additional 99,795 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of OPKO Health during the fourth quarter valued at about $1,657,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost purchased 67,434 shares of the company’s stock in a transaction on Friday, February 28th. The shares were bought at an average price of $1.71 per share, for a total transaction of $115,312.14. Following the completion of the purchase, the chief executive officer now owns 213,301,448 shares of the company’s stock, valued at $364,745,476.08. This trade represents a 0.03% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have purchased 767,434 shares of company stock valued at $1,238,312 over the last three months. Company insiders own 49.69% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Monday, April 7th. Barrington Research reiterated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Thursday, May 1st. JPMorgan Chase & Co. assumed coverage on OPKO Health in a research note on Friday, April 25th. They issued a “neutral” rating for the company. Finally, StockNews.com downgraded OPKO Health from a “hold” rating to a “sell” rating in a research note on Monday, May 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $2.75.

OPKO Health Price Performance

OPK opened at $1.33 on Friday. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The company’s 50-day moving average price is $1.51 and its 200 day moving average price is $1.56. OPKO Health, Inc. has a fifty-two week low of $1.19 and a fifty-two week high of $2.04. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -7.00 and a beta of 1.42.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). The company had revenue of $149.90 million for the quarter, compared to analyst estimates of $163.13 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm’s revenue for the quarter was down 13.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.12) earnings per share. As a group, sell-side analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.